Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Reck

Showing results (51-60 of 114) with videos related to

Pageof 12
Sort By:
Drug and Alcohol Dependence|September 30, 2022
Assessment of dependence potential and abuse liability of Δ<sup>8</sup>-tetrahydrocannabinol in miceS O Vanegas, A M Reck, C E Rodriguez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2012
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialM Reck, I Bondarenko, A Luft, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2014
Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)N Reinmuth, A Meyer, D Hartwigsen, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 7, 2018
Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESSE Arriola, A Paredes-Lario, R García-Gomez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2010
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)M Reck, J von Pawel, P Zatloukal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2012
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancerJ-C Soria, A Mauguen, M Reck, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2004
A vascular cell-restricted RhoGAP, p73RhoGAP, is a key regulator of angiogenesisZhi-Jian Su, Christopher N Hahn, Gregory J Goodall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseB Besse, A Adjei, P Baas, et al.
Virchows Archiv : an International Journal of Pathology|August 9, 2019
Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patientsC Kuempers, L I S van der Linde, M Reischl, et al.
Deutsche Medizinische Wochenschrift (1946)|October 1, 2014
[Molecular genetic tests in advanced non-small cell lung cancer: practical relevance]M Sebastian, N Niederle, M Thomas, et al.
Pageof 12

Showing results (51-60 of 114) with videos related to

Sort By:
Pageof 12
Drug and Alcohol Dependence|September 30, 2022
Assessment of dependence potential and abuse liability of Δ<sup>8</sup>-tetrahydrocannabinol in miceS O Vanegas, A M Reck, C E Rodriguez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2012
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialM Reck, I Bondarenko, A Luft, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2014
Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)N Reinmuth, A Meyer, D Hartwigsen, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 7, 2018
Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESSE Arriola, A Paredes-Lario, R García-Gomez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2010
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)M Reck, J von Pawel, P Zatloukal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2012
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancerJ-C Soria, A Mauguen, M Reck, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2004
A vascular cell-restricted RhoGAP, p73RhoGAP, is a key regulator of angiogenesisZhi-Jian Su, Christopher N Hahn, Gregory J Goodall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseB Besse, A Adjei, P Baas, et al.
Virchows Archiv : an International Journal of Pathology|August 9, 2019
Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patientsC Kuempers, L I S van der Linde, M Reischl, et al.
Deutsche Medizinische Wochenschrift (1946)|October 1, 2014
[Molecular genetic tests in advanced non-small cell lung cancer: practical relevance]M Sebastian, N Niederle, M Thomas, et al.
Pageof 12